Overview

ALS Treatment Extension Study

Status:
Unknown status

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

Treatment extension study for ALS/MND patients who participated in phase 1 study CMD-2016-001, completed assessments following six 28-day cycles of treatment, and whom the Investigator considers would benefit from continued CuATSM treatment.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Collaborative Medicinal Development Pty Limited

Treatments:

Copper